检索结果-南通市图书馆

head-to-head comparison of h_2-receptor antagonists and proton pump inhibitors in the treatment of erosive esophagitis: A meta-analysis

引用

World Journal of Gastroenterology 2005年第26期11卷 4067-4077页

作者： Wei-hongWang Jia-Qinghuang Ge-FanZheng harryhua-XiangXia Wai-ManWong Shiu-KumLam BenjaminChun-YuWong DepartmentofGastroenterology PekingUniversityFirstHospitalBeijingChina//DepartmentofMedicineFacultyofMedicineUniversityofHongKongHongKongChina//ContributedEquallytoThisWork DepartmentofMedicine FacultyofMedicineUniversityofHongKongHongKongChina DepartmentofMedicine FacultyofMedicineUniversityofHongKongHongKongChina//contributedEquallytoThisWord

AIM: To systematically evaluate the efficacy of h2-receptor antagonists (h2RAs) and proton pump inhibitors in healing erosive esophagitis (EE).METhODS: A meta-analysis was performed. A literature search was conducted in PubMed, Medline, Embase, and Cochrane databases to include randomized controlled head-to-head comparative trials evaluating the efficacy of h2RAs or proton pump inhibitors in healing EE. Relative risk (RR) and 95% confidence interval (CI) were calculated under a random-effects ***: RRs of cumulative healing rates for each comparison at 8 wk were: high dose vs standard dose h2RAs,1.17 (95%CI, 1.02-1.33); standard dose proton pump inhibitors vsstandard dose h2RAs, 1.59 (95%CI, 1.44-1.75);standard dose other proton pump inhibitors vs standard dose omeprazole, 1.06 (95%CI, 0.98-1.06). Proton pump inhibitors produced consistently greater healing rates than h2RAs of all doses across all grades of esophagitis, including patients refractory to h2RAs. healing rates achieved with standard dose omeprazole were similar to those with other proton pump inhibitors in all grades of ***: h2RAS are less effective for treating patients with erosive esophagitis, especially in those with severe forms of esophagitis. Standard dose proton pump inhibitors are significantly more effective than h2RAs in healing esophagitis of all grades. Proton pump inhibitors given at the recommended dose are equally effective for healing esophagitis.

关键词： Erosive esophagitis h2-receptor antagonists Proton pump inhibitors Meta-analysis

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

A Prospective, Multicentric, Post Marketing Surveillance to Evaluate Efficacy & Safety of Ranitidine hCl (150 & 300 mg IR/CR) in Indian Patients with Gastroesophageal Reflux Disease (PROGRADE)

引用

Open Journal of Gastroenterology 2023年第7期13卷 237-249页

作者： Akash Shukla Anil Kumar Awasthi Ramesh Rao Dawesh Prakash Yadav Nilesh Nolkha Rajesh Pendlimari Sanjiv Dua Shrish Bhatnagar Ravindra Mote Ashish Birla Jay Savai Kapil Mehta Shashank Salunke Department of Gastroenterology Gastro Universe Mumbai India Department of Medicine Ajanta Research Centre Ajanta Hospital & IVF Centre Lucknow India Departmentof Nephrology Sanjeevani Kidney Care Mumbai India Department of Gastroenterology Institute of Medical Sciences Banaras Hindu University Varanasi India Department of Rheumatology Wockhardt Hospitals Mumbai India Department of Gastroenterology Rajalakshmi Hospital and Research Center Bangalore India Department of General Surgery SaiKripa Hospital Mumbai India Department of Gastroenterology Sparsh Child Care and Gastro Centre Lucknow India Department of Clinical Research Mediclin Clinical Research Mumbai India Department of Medical Affairs JB Chemicals & Pharmaceuticals Ltd. Mumbai India

Purpose: Ranitidine hydrochloride (hCl) remains an important medication for treating acid-peptic ailments such as Gastroesophageal reflux disease (GERD). The main objective of this Post Marketing Surveillance (PMS) clinical study was to test the efficacy and safety of Ranitidine hCl in Indian patients suffering from GERD. Patients and Methods: Data of 2446 patients (1307 males;1121 females) from 21 centers across India were analyzed. Patients received either of the three treatments: Ranitidine hCl 150 mg twice a day (BID) (ARM-A), Ranitidine hCl 300 mg once daily (OD) or BID (ARM-B), and Ranitidine hCl 300 mg OD (ARM-C). Gastroesophageal Reflux Disease Symptom Assessment Scale (GSAS) score and heartburn Severity score were used to assess the drug’s efficacy. The adverse events reported by patients or investigators were analyzed to assess the safety profile of Ranitidine. Results: Of the 2446 subjects screened, 2428 were enrolled. There was a significant reduction in GSAS scores from baseline to the end of the study visit in all three ARMs. The GSAS scores reduced from 2.02 to 0.23 in ARM-A, 2.01 to 0.24 in ARM-B, and 2.07 to 0.26 in ARM-C patients. In ARM A, 72.82% had 24 hours heartburn-free days, and 66.89% had 7 consecutive heartburn-free days, which was more significant than the other two ARMs. 128 (5.27%) patients reported ADRs due to Ranitidine hCl at different doses. The most frequently reported ADR was constipation (17.18%), followed by oliguria (14.06%), cold (13.28%), and dysuria (12.5%). Of 128 ADRs, 113 (88.28%) were mild, and only 11 (8.59%) ADRs were related to the study drug. No severe ADRs were reported during the study. Conclusion: Ranitidine hCl 150/300 mg tablet was found to be an effective and safe h2-receptor antagonist for treating GERD in Indian Patients.

关键词： Ranitidine hydrochloride GERD heartburn h2-receptor antagonists

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：